Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression

Lisa D. Mills, Lizhi Zhang, Ronald J Marler, Phyllis Svingen, Maite G. Fernandez-Barrena, Maneesh Dave, William Bamlet, Robert R Mc Williams, Gloria M Petersen, William Alvis Faubion, Martin E Fernandez-Zapico

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The role of GLI1 in pancreatic tumor initiation promoting the progression of preneoplastic lesions into tumors is well established. However, its function at later stages of pancreatic carcinogenesis remains poorly understood. To address this issue, we crossed the gli1 knock-out (GKO) animal with cre-dependent pancreatic activation of oncogenic kras concomitant with loss of the tumor suppressor tp53 (KPC). Interestingly, in this model, GLI1 played a tumor-protective function, where survival of GKO/KPC mice was reduced compared with KPC littermates. Both cohorts developed pancreatic cancer without significant histopathological differences in survival studies. However, analysis of mice using ultrasound-based imaging at earlier time points showed increased tumor burden in GKO/KPC mice. These animals have larger tumors, decreased body weight, increased lactate dehydrogenase production, and severe leukopenia. In vivo and in vitro expression studies identified FAS and FAS ligand (FASL) as potential mediators of this phenomenon. The FAS/FASL axis, an apoptotic inducer, plays a role in the progression of pancreatic cancer, where its expression is usually lost or significantly reduced in advanced stages of the disease. Chromatin immunoprecipitation and reporter assays identified FAS and FASL as direct targets of GLI1, whereas GKO/KPC mice showed lower levels of this ligand compared with KPC animals. Finally, decreased levels of apoptosis were detected in tumor tissue in the absence of GLI1 by TUNEL staining. Together, these findings define a novel pathway regulated by GLI1 controlling pancreatic tumor progression and provide a new theoretical framework to help with the design and analysis of trials targeting GLI1-related pathways.

Original languageEnglish (US)
Pages (from-to)16516-16525
Number of pages10
JournalJournal of Biological Chemistry
Volume289
Issue number23
DOIs
StatePublished - Jun 6 2014

Fingerprint

Pancreatic Neoplasms
Tumors
Transcription Factors
Neoplasms
Knockout Mice
Ligands
Animals
Chromatin Immunoprecipitation
In Situ Nick-End Labeling
Leukopenia
Tumor Burden
L-Lactate Dehydrogenase
Ultrasonography
Carcinogenesis
Chromatin
Assays
Body Weight
Apoptosis
Staining and Labeling
Ultrasonics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. / Mills, Lisa D.; Zhang, Lizhi; Marler, Ronald J; Svingen, Phyllis; Fernandez-Barrena, Maite G.; Dave, Maneesh; Bamlet, William; Mc Williams, Robert R; Petersen, Gloria M; Faubion, William Alvis; Fernandez-Zapico, Martin E.

In: Journal of Biological Chemistry, Vol. 289, No. 23, 06.06.2014, p. 16516-16525.

Research output: Contribution to journalArticle

Mills, Lisa D. ; Zhang, Lizhi ; Marler, Ronald J ; Svingen, Phyllis ; Fernandez-Barrena, Maite G. ; Dave, Maneesh ; Bamlet, William ; Mc Williams, Robert R ; Petersen, Gloria M ; Faubion, William Alvis ; Fernandez-Zapico, Martin E. / Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 23. pp. 16516-16525.
@article{7a2a172ebdca43ada0ab33ab67bb6cd7,
title = "Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression",
abstract = "The role of GLI1 in pancreatic tumor initiation promoting the progression of preneoplastic lesions into tumors is well established. However, its function at later stages of pancreatic carcinogenesis remains poorly understood. To address this issue, we crossed the gli1 knock-out (GKO) animal with cre-dependent pancreatic activation of oncogenic kras concomitant with loss of the tumor suppressor tp53 (KPC). Interestingly, in this model, GLI1 played a tumor-protective function, where survival of GKO/KPC mice was reduced compared with KPC littermates. Both cohorts developed pancreatic cancer without significant histopathological differences in survival studies. However, analysis of mice using ultrasound-based imaging at earlier time points showed increased tumor burden in GKO/KPC mice. These animals have larger tumors, decreased body weight, increased lactate dehydrogenase production, and severe leukopenia. In vivo and in vitro expression studies identified FAS and FAS ligand (FASL) as potential mediators of this phenomenon. The FAS/FASL axis, an apoptotic inducer, plays a role in the progression of pancreatic cancer, where its expression is usually lost or significantly reduced in advanced stages of the disease. Chromatin immunoprecipitation and reporter assays identified FAS and FASL as direct targets of GLI1, whereas GKO/KPC mice showed lower levels of this ligand compared with KPC animals. Finally, decreased levels of apoptosis were detected in tumor tissue in the absence of GLI1 by TUNEL staining. Together, these findings define a novel pathway regulated by GLI1 controlling pancreatic tumor progression and provide a new theoretical framework to help with the design and analysis of trials targeting GLI1-related pathways.",
author = "Mills, {Lisa D.} and Lizhi Zhang and Marler, {Ronald J} and Phyllis Svingen and Fernandez-Barrena, {Maite G.} and Maneesh Dave and William Bamlet and {Mc Williams}, {Robert R} and Petersen, {Gloria M} and Faubion, {William Alvis} and Fernandez-Zapico, {Martin E}",
year = "2014",
month = "6",
day = "6",
doi = "10.1074/jbc.M113.539031",
language = "English (US)",
volume = "289",
pages = "16516--16525",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "23",

}

TY - JOUR

T1 - Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression

AU - Mills, Lisa D.

AU - Zhang, Lizhi

AU - Marler, Ronald J

AU - Svingen, Phyllis

AU - Fernandez-Barrena, Maite G.

AU - Dave, Maneesh

AU - Bamlet, William

AU - Mc Williams, Robert R

AU - Petersen, Gloria M

AU - Faubion, William Alvis

AU - Fernandez-Zapico, Martin E

PY - 2014/6/6

Y1 - 2014/6/6

N2 - The role of GLI1 in pancreatic tumor initiation promoting the progression of preneoplastic lesions into tumors is well established. However, its function at later stages of pancreatic carcinogenesis remains poorly understood. To address this issue, we crossed the gli1 knock-out (GKO) animal with cre-dependent pancreatic activation of oncogenic kras concomitant with loss of the tumor suppressor tp53 (KPC). Interestingly, in this model, GLI1 played a tumor-protective function, where survival of GKO/KPC mice was reduced compared with KPC littermates. Both cohorts developed pancreatic cancer without significant histopathological differences in survival studies. However, analysis of mice using ultrasound-based imaging at earlier time points showed increased tumor burden in GKO/KPC mice. These animals have larger tumors, decreased body weight, increased lactate dehydrogenase production, and severe leukopenia. In vivo and in vitro expression studies identified FAS and FAS ligand (FASL) as potential mediators of this phenomenon. The FAS/FASL axis, an apoptotic inducer, plays a role in the progression of pancreatic cancer, where its expression is usually lost or significantly reduced in advanced stages of the disease. Chromatin immunoprecipitation and reporter assays identified FAS and FASL as direct targets of GLI1, whereas GKO/KPC mice showed lower levels of this ligand compared with KPC animals. Finally, decreased levels of apoptosis were detected in tumor tissue in the absence of GLI1 by TUNEL staining. Together, these findings define a novel pathway regulated by GLI1 controlling pancreatic tumor progression and provide a new theoretical framework to help with the design and analysis of trials targeting GLI1-related pathways.

AB - The role of GLI1 in pancreatic tumor initiation promoting the progression of preneoplastic lesions into tumors is well established. However, its function at later stages of pancreatic carcinogenesis remains poorly understood. To address this issue, we crossed the gli1 knock-out (GKO) animal with cre-dependent pancreatic activation of oncogenic kras concomitant with loss of the tumor suppressor tp53 (KPC). Interestingly, in this model, GLI1 played a tumor-protective function, where survival of GKO/KPC mice was reduced compared with KPC littermates. Both cohorts developed pancreatic cancer without significant histopathological differences in survival studies. However, analysis of mice using ultrasound-based imaging at earlier time points showed increased tumor burden in GKO/KPC mice. These animals have larger tumors, decreased body weight, increased lactate dehydrogenase production, and severe leukopenia. In vivo and in vitro expression studies identified FAS and FAS ligand (FASL) as potential mediators of this phenomenon. The FAS/FASL axis, an apoptotic inducer, plays a role in the progression of pancreatic cancer, where its expression is usually lost or significantly reduced in advanced stages of the disease. Chromatin immunoprecipitation and reporter assays identified FAS and FASL as direct targets of GLI1, whereas GKO/KPC mice showed lower levels of this ligand compared with KPC animals. Finally, decreased levels of apoptosis were detected in tumor tissue in the absence of GLI1 by TUNEL staining. Together, these findings define a novel pathway regulated by GLI1 controlling pancreatic tumor progression and provide a new theoretical framework to help with the design and analysis of trials targeting GLI1-related pathways.

UR - http://www.scopus.com/inward/record.url?scp=84902123178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902123178&partnerID=8YFLogxK

U2 - 10.1074/jbc.M113.539031

DO - 10.1074/jbc.M113.539031

M3 - Article

C2 - 24737325

AN - SCOPUS:84902123178

VL - 289

SP - 16516

EP - 16525

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 23

ER -